

Investment forum, this year, will provide Asia bio health industry and investment trends from global venture capitalists and economists. And it will also provide global investment attracting strategy for bio health innovative companies by investigating Korea pharma fund and some successful investment cases.

SESSION 1. ASIA BIO-HEALTH BUSINESS TREND AND COOPERATION STRATEGY FOR GLOBAL INVESTMENT ACTIVATION

April 8(Wed) 14:00 ~ 17:00

SESSION CHAIR Jung Hyun Kim, CEO, Solidus Investment, Korea

14:00 ~ 14:30 **Singapore Exchange (SGX) – A Choice Market for Capital Raising**
Alvin Soh, Senior Vice President, UOB Kay Hian Private Limited, Singapore

14:30 ~ 15:00 **Asian Biotech Sector: A Singapore Perspective**
Kang Lin Ong, Managing Partner, Black Stallion Capital Pte LLP., Singapore

15:00 ~ 15:30 **Bio-health Investment Trend in China**
Lin Yi, Director, Korea Investment Partners Co.,Ltd. (Beijing), China

15:30 ~ 16:00 **Australia's Life Sciences Sector - An Investment Opportunity**
Glenn Cross, Chief Operation Officer, AusBiotech Ltd., Australia

16:00 ~ 16:15 Session Break

Comparison of Bio-health Investment Trends and Cooperative Strategy for Global Investment Activation

Chair Eun Hyun Chan, Ph.D., Atinum Investment

Panel Michael J. Kim, UTR Investment Group, Singapore

Adrian Seow, Black Stallion Capital, Singapore

Won Jae Lee, Korea Head of the Office, Yozma Group, Korea

Lin Yi, Director, Korea Investment Partners Co.,Ltd. (Beijing), China

Glenn Cross, Chief Operation Officer, AusBiotech Ltd., Australia

16:15 ~ 17:00

SESSION 2. INVESTMENT SELECTION POINT OF KOREAN VENTURE CAPITALISTS AND INVESTMENT ATTRACTING STRATEGY FOR COMPANIES

April 9(Thur) 10:00 ~ 12:30

SESSION CHAIR Jung Hae Seo, Ph.D., KDI, Korea

10:00 ~ 10:30 **Korea (and Asia) Bio Health Industry and Investment Trend**
Su Yong Chung, Consultant, IMS, Korea

10:30 ~ 11:10 **InterVest Global Pharmaceutical Fund**
Myung Ki Kim, Executive Director, Interinvest, Korea

KIP Global Pharma-Ecosystem Private Equity Fund
Man Soon Hwang, Executive Director, Korea Investment Partners Co., Ltd., Korea

11:10 ~ 11:40 **Pharm-Biotech Collaboration through Strategic Investment; Handok-Genexin Case**
Woo Ick Chang, Vice President, Handok, Korea

11:40 ~ 12:10 **The Case of Successful Cooperation with Global Pharma Company**
Yup Yoon, Director of the headquarters, Samsung Medical Center, Korea

12:10 ~ 12:30 **Investment Direction of Yozma Group and Introduction of Korea Yozma Campus**
Won Jae Lee, Korea Head of the Office, Yozma Group, Korea

SESSION 3. IR PRESENTATION APRIL 9(THUR) 14:00 ~ 16:30

14:00 ~ 14:20	<p>T&R Biofab (Intro: Korea Investment Partners) 'Tissue regeneration based on 3D printing technology' Won Su Yoon, Korea</p>
14:20 ~ 14:40	<p>Genomictree (Intro: KB Investment) 'Developing Cancer Diagnostic Tests Using Cancer-Specific Biomarkers' Sung Hwan Ahn, CEO, Korea</p>
14:40 ~ 15:00	<p>Abion (Intro: KDB Capital) 'Perpetual Pharmaceutical Pearl Provider' Sang Ho Park, Vice President, Korea</p>
15:00 ~ 15:10	Session Break
15:10 ~ 15:30	<p>Medpacto (Intro: Neoplux) 'TEW-7197, ALK5 Inhibitor - Synergism with Immuno-cancer Therapy' Il HO Ha, CEO, Korea</p>
15:30 ~ 15:50	<p>Qurient (Intro: SBI Investment) 'Innovation for Cancer and Inflammatory Diseases' Ki Yeon Nam, CEO, Korea</p>
15:50 ~ 16:10	<p>Cellumed (Intro: UTR Singapore) 'Development of Protein Material for Tissue Regeneration' Sung Baek Lee, General Manager, Korea</p>
16:10 ~ 16:30	<p>Bioleaders (Intro: Solidus Investment) 'Global New Drug Development' Sang Seock Kim, CEO, Korea</p>